🚀 VC round data is live in beta, check it out!
Biofrontera Valuation Multiples
Discover revenue and EBITDA valuation multiples for Biofrontera and similar public comparables like Xintela, Celyad Oncology, Anebulo Pharmaceuticals, BioAtla and more.
Biofrontera Overview
About Biofrontera
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.
Founded
1997
HQ
Employees
88
Website
Financials (FY)
EV
$15M
Biofrontera Financials
Biofrontera reported last fiscal year revenue of $25M and negative EBITDA of ($7M).
In the same fiscal year, Biofrontera generated $19M in gross profit, ($7M) in EBITDA losses, and had net loss of ($5M).
Revenue (LTM)
Biofrontera P&L
In the most recent fiscal year, Biofrontera reported revenue of $25M and EBITDA of ($7M).
Biofrontera expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $25M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $19M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 75% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($7M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (27%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (27%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($5M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (20%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Biofrontera Stock Performance
Biofrontera has current market cap of $19M, and enterprise value of $15M.
Market Cap Evolution
Biofrontera's stock price is $3.09.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15M | $19M | -0.6% | XXX | XXX | XXX | $-0.82 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiofrontera Valuation Multiples
Biofrontera trades at 0.6x EV/Revenue multiple, and (2.2x) EV/EBITDA.
EV / Revenue (LTM)
Biofrontera Financial Valuation Multiples
As of April 5, 2026, Biofrontera has market cap of $19M and EV of $15M.
Equity research analysts estimate Biofrontera's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biofrontera has a P/E ratio of (3.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19M | XXX | $19M | XXX | XXX | XXX |
| EV (current) | $15M | XXX | $15M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.2x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (2.2x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 0.8x | XXX | XXX | XXX |
| P/E | — | XXX | (3.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biofrontera Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Biofrontera Margins & Growth Rates
Biofrontera's revenue in the last fiscal year declined by (33%).
Biofrontera's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
Biofrontera Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (33%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (27%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 344% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 32% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 46% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 25% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 103% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Biofrontera Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Xintela | XXX | XXX | XXX | XXX | XXX | XXX |
| Celyad Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Anebulo Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| BioAtla | XXX | XXX | XXX | XXX | XXX | XXX |
| Oncoinvent | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biofrontera M&A Activity
Biofrontera acquired XXX companies to date.
Last acquisition by Biofrontera was on XXXXXXXX, XXXXX. Biofrontera acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Biofrontera
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBiofrontera Investment Activity
Biofrontera invested in XXX companies to date.
Biofrontera made its latest investment on XXXXXXXX, XXXXX. Biofrontera invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Biofrontera
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biofrontera
| When was Biofrontera founded? | Biofrontera was founded in 1997. |
| Where is Biofrontera headquartered? | Biofrontera is headquartered in Germany. |
| How many employees does Biofrontera have? | As of today, Biofrontera has over 88 employees. |
| Is Biofrontera publicly listed? | Yes, Biofrontera is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of Biofrontera? | Biofrontera trades under B8FK ticker. |
| When did Biofrontera go public? | Biofrontera went public in 2007. |
| Who are competitors of Biofrontera? | Biofrontera main competitors are Xintela, Celyad Oncology, Anebulo Pharmaceuticals, BioAtla. |
| What is the current market cap of Biofrontera? | Biofrontera's current market cap is $19M. |
| What is the current revenue of Biofrontera? | Biofrontera's last fiscal year revenue is $25M. |
| What is the current EV/Revenue multiple of Biofrontera? | Current revenue multiple of Biofrontera is 0.6x. |
| Is Biofrontera profitable? | No, Biofrontera is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.